UC San Francisco study: Hormone therapy could mask prostate cancer risk in trans women

In a reported “first-of-its-kind” study in the U.S., researchers at the University of California San Francisco have determined that transgender women have a “small but meaningful” prostate cancer risk.

The study, “Prostate Cancer in Transgender Women in the Veterans Affairs Health System, 2000-2022” published in the Journal of the American Medical Association late last week, points out that “transgender women retain their prostate even after gender-affirmation surgery and thus remain at risk of prostate cancer.”

However, researchers found incidences of the disease were lower in transgender women than cisgender males, partly due to “gender-affirming” treatments such as hormone therapy.

This content is a work of satire and parody. Any resemblance to actual persons, living or dead, or actual events is purely coincidental. Any opinions expressed in this content do not reflect the views of the author or publisher. In fact, they probably reflect the opposite of the views of the author or publisher. The purpose of this content is to entertain and possibly make you question the reality of the world around you. So please, don't take anything too seriously, unless it's the importance of a good laugh.
Doctor with a stethoscope by Online Marketing is licensed under Unsplash unsplash.com

Get latest news delivered daily!

We will send you breaking news right to your inbox

© 2024 wokelish.com